MedTrace Logo

The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery

NCT02164565 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-08-16

No results posted yet for this study

Summary

The use of Tranexamic Acid (TXA) intravenously, to Reduce Blood Loss in proximal femur surgery.

Conditions

  • Femur Surgery

Interventions

DRUG

Tranexamic Acid (TXA) treatment

Tranexamic Acid (TXA) treatment

DRUG

control grup: without Tranexamic Acid (TXA) treatment.

control grup: without Tranexamic Acid (TXA) treatment.

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • Nimrod Rozen, Prof. · Division of Orthopedic & Rehabilitatio, HaEmek Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-01-31
Completion
2015-03-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02164565 on ClinicalTrials.gov